Business Monitor International


Czech Republic Pharmaceuticals & Healthcare Report

Published 31 December 2014

  • 109 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Czech Republic Pharmaceuticals & Healthcare Report

BMI View: Czech Republic's disease and drug consumption profile illustrates a considerable gap between it and Western Europe, suggesting that the population's demand for high-value innovative medicines will continue until convergence. The healthcare spending of the Czech population remains superior to that of the less-developed markets of Eastern and South Eastern Europe, demonstrating that demand in these regions will be even higher. However, the government's short-term ability to provide these medicines remains a key challenge.

Headline Expenditure Projections

  • Pharmaceuticals: CZK76.93bn (USD3.66bn) in 2013 to CZK74.24bn (USD3.38bn) in 2014; -3.5% in local currency terms and -7.6% in US dollar terms. Forecasts significantly lower compared to previous quarter.

  • Healthcare: CZK290.94bn (USD13.83bn) in 2013 to CZK303.17bn (USD13.81bn) in 2014; +4.2% in local currency terms and -0.2% in US dollar terms. Forecasts changed due to historical revision to 2012 figures.

Risk/Reward Index: Despite placing second in our regional Q115 RRI table with a score of 60.8 out of 100, and therefore ranked as the second most attractive market in the Central and Eastern European - beaten only by Poland (61.5) and followed closely by Greece (57.9), drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure, poor access to the market and increasing generic substitution. Additionally, adopted and proposed amendments to healthcare and insurance laws have attracted criticism from the pharmaceutical sector. The Czech pharmaceutical market will nevertheless remain relatively attractive and rewarding due to the regionally high pharmaceutical expenditure per capita compared with its neighbours, an ageing population and a favourable urban-rural distribution.

Key Trends And Developments

In November 2014, food supplement supplier Walmark expanded its portfolio through the acquisition of a range of products marketed under the Sinulan Forte brand...

Table of Contents

BMI Industry View
7
SWOT
11
Political
13
Economic
14
Business Environment
15
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2010-2018)
18
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
24
Prescription Drug Market Forecast
25
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
26
Patented Drug Market Forecast
27
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
28
Generic Drug Market Forecast
29
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2012-2018)
34
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Czech Republic 2012-2018)
34
Other Healthcare Data
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
37
Economic Analysis
37
Table: Economic Activity (Czech Republic 2009-2018)
39
Industry Risk Reward Ratings
40
Central And Eastern Europe Risk/Reward Ratings
40
Czech Republic Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Healthcare Sector
50
Healthcare Insurance
51
Healthcare Reforms
52
Hospital Sector
56
Research & Development
56
Clinical Trials
59
Regulatory Development
61
Regulatory Regime
61
Intellectual Property Environment
61
Prescribing Rules
62
Pharmaceutical Advertising
62
Pricing Regime
64
Reimbursement Regime
64
Recent Pricing And Reimbursement Developments
65
Changes To VAT
69
Table: European VAT Rates On Medicines (%)
70
Electronic Tenders
71
Competitive Landscape
72
Pharmaceutical Sector
72
Foreign Industry
73
Pharmaceutical Wholesale
74
Pharmaceutical Retail Sector
74
Table: Retail Pharmacy Market Overview, 2006-2012
74
Company Profile
77
Zentiva (Sanofi)
77
Walmark
81
AstraZeneca
85
Bristol-Myers Squibb
87
Sanofi
89
Novartis
92
GlaxoSmithKline
94
Pfizer
97
Demographic Forecast
99
Table: The Czech Republic's Population By Age Group, 1990-2020 ('000)
100
Table: The Czech Republic's Population By Age Group, 1990-2020 (% of total)
101
Table: The Czech Republic's Key Population Ratios, 1990-2020
102
Table: The Czech Republic's Rural And Urban Population, 1990-2020
102
Glossary
103
Methodology
105
Pharmaceutical Expenditure Forecast Model
105
Healthcare Expenditure Forecast Model
105
Notes On Methodology
106
Risk/Reward Ratings Methodology
107
Ratings Overview
108
Table: Pharmaceutical Risk/Reward Ratings Indicators
108
Indicator Weightings
109

The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc